Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Biosight Ltd. logo — Developing innovative pharmaceuticals for hematological mali...

Biosight Ltd.

Developing innovative pharmaceuticals for hematological malignancies and disorders

Founded 2000 Israel Israel 3 employees Series C Total: $59.00M Biotechnology, Health Care +2

General Information

Company Name Biosight Ltd.
Founded Year 2000
Location Israel Israel
Employees 3
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Biosight Ltd.. To contact Biosight Ltd., visit biosight-pharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Biosight Ltd. compare?

A PDF of Biosight Ltd. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Biosight Ltd. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Biosight Ltd.

Biosight Ltd. is a biotech company founded in 2000, headquartered in Israel, and is currently in the Phase 2 clinical stage of development. The company is focused on developing innovative pharmaceuticals for hematological malignancies and disorders, with its lead product, BST-236 (aspacytarabine), showing promising results. The drug addresses unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity. Recently, Biosight secured a $27.00M Series C investment on 02 December 2020 from a group of investors including Primera Capital, Israel Biotech Fund, Migdal Insurance and Financial Holdings, Arkin Bio Ventures, Phoenix Insurance Company, and Biotel. The company's progression to Phase 2b for the first-line treatment of acute myeloid leukemia (AML), as well as the upcoming Phase 2 study for relapsed/refractory AML and myelodysplastic syndrome (MDS) in collaboration with GFM, demonstrates the substantial potential of Biosight's offerings in addressing critical medical challenges. The alliance with the European cooperative group further validates Biosight's commitment to advancing therapeutic solutions and could potentially open doors to a broader market.

Business keywords: Pharmaceutical development, Biotech, Acute myeloid leukemia, Myelodysplastic syndrome, Hematological malignancies, Chemotherapy, Clinical stage biotech, Phase 2 clinical, Innovative therapeutics, Targeted chemotherapy, Pro-drugs, AML treatment, MDS treatment

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $27.00M 6
Primera Capital Israel Biotech Fund
Primera Capital, Israel Biotech Fund +4
02 Dec 2020
Series C $19.00M 3
Israel Biotech Fund
Israel Biotech Fund, Arkin Bio Ventures +1
11 Mar 2020
Venture Round $13.00M 1
Arkin Holdings
Arkin Holdings
16 May 2016
Venture Round Undisclosed -
01 Jan 2007

Biosight Ltd. Alternatives & Competitors

View All Alternatives
Biosight Ltd. vs
Chordia Therapeutics Inc
Chordia Therapeutics Inc Japan

We are passionate to deliver first in class cancer drugs to patients from Japan.

IPO
11 employees
Biotechnology, Health Care
Biosight Ltd. vs
Syros Pharmaceuticals
Syros Pharmaceuticals United States

By redefining the power of small molecules to control gene expression, we aim to provide a profound...

IPO
88 employees
Biotechnology, Life Sciences
Compare Biosight Ltd. vs Syros Pharmaceuticals
Biosight Ltd. vs
March Biosciences
March Biosciences United States

Transforming patient care in the most challenging leukemias and lymphomas

Grant
12 employees
Health Care, Health and Wellness
View all alternatives

FAQ About Biosight Ltd.

Developing innovative pharmaceuticals for hematological malignancies and disorders
Biosight Ltd. was founded in 2000.
Biosight Ltd. is headquartered in Israel.
Biosight Ltd. operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on Pharmaceutical development, Biotech, Acute myeloid leukemia and Myelodysplastic syndrome.
Biosight Ltd. has approximately 3 employees.
Biosight Ltd. has completed 4 funding rounds, raising a total of $59.00M. The latest funding stage is Series C.
Top alternatives and competitors to Biosight Ltd. include Chordia Therapeutics Inc, Syros Pharmaceuticals, March Biosciences, Cantargia AB, ProfoundBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biosight Ltd. and Chordia Therapeutics Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Biosight Ltd., https://bouncewatch.com/company/biosight-ltd, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes